Hand transplantation

Hand transplantation is a surgical procedure in which a hand or upper extremity from a deceased donor is transferred to a recipient who has sustained loss of one or both hands. It is a form of vascularized composite allotransplantation (VCA), meaning the graft contains multiple tissue types, including skin, fat, muscle, tendon, bone, blood vessels, and nerves, transplanted together as a single functional unit.[1][2] Unlike most organ transplantation, hand transplantation is not life-saving but life-enhancing, and it requires the recipient to take lifelong immunosuppressive medication. This trade-off, between improved function and quality of life on one hand and the risks of immunosuppression on the other, is central to the field's clinical and ethical debate.[3]

Classification as a VCA

Hand transplantation is classified as a vascularized composite allograft because the graft is a composite of several tissue types served by a common blood supply, rather than a single homogeneous organ such as a kidney or liver.[1][2] In the United States, the Organ Procurement and Transplantation Network (OPTN) began regulating VCA on July 3, 2014, when VCAs were formally added to the federal definition of "organ" under the OPTN Final Rule (42 CFR part 121). After that date, centers performing VCAs were required to report standardized data, including recipient demographics, waiting times, donor authorization, and clinical outcomes.[4][5] The skin component of the graft is the most antigenic tissue and is the principal target of immune rejection, which distinguishes VCA immunologically from solid-organ transplantation.[6]

Indications

Hand transplantation is considered for patients with traumatic or surgical loss of one (unilateral) or both (bilateral) hands or portions of the upper extremity, where conventional reconstruction and prosthetics have not produced acceptable function or quality of life.[3][7] Amputations are described by level, and outcomes and the extent of recovery differ depending on whether the amputation is distal (more peripheral, for example below the elbow) or proximal (above the elbow), because the distance over which nerves must regenerate affects functional return.[8] Bilateral amputees are often regarded as having the most to gain functionally, since restoring even partial bimanual function can substantially improve independence in daily activities.[3][7]

Recipient selection and the rehabilitation burden

Because hand transplantation is elective and not life-saving, candidate selection involves careful medical and psychiatric screening. Evaluation assesses a candidate's psychological resilience, motivation, and capacity to integrate the transplanted hand into their body image, as well as the ability to adhere to a demanding postoperative regimen.[3] Adherence is critical: the most-cited early graft loss in the field, that of Clint Hallam, followed his discontinuation of immunosuppression and rehabilitation.[3][9]

The rehabilitation burden is substantial. Recovery of useful motor and sensory function depends on nerve regeneration, which proceeds slowly, at a rate of roughly one inch (about 2.5 cm) per month, so function returns gradually over months to years rather than immediately after surgery.[8] Recipients commit to intensive, prolonged hand therapy and to lifelong adherence to immunosuppressive medication and monitoring.[3][8]

Surgical technique

Hand transplantation follows a structured sequence designed to rebuild the limb tissue by tissue. After the donor graft is procured and the recipient stump prepared, the operation typically proceeds with bone fixation first, approximating and plating the radius and ulna to establish a stable skeletal framework. Tendons are then repaired (both flexor and extensor groups), followed by anastomosis of the blood vessels (arteries and veins) to restore circulation to the graft, repair (coaptation) of the nerves to allow eventual return of sensation and motor control, and finally closure of the soft tissue and skin.[7][10] These operations are lengthy and technically demanding; the first successful procedures lasted on the order of 13 to 14 hours.[9][11]

Immunosuppression regimen

The standard approach mirrors that of solid-organ transplantation but is adapted to the high antigenicity of skin. Most recipients receive lymphocyte-depleting induction therapy (agents such as antithymocyte globulin/thymoglobulin or alemtuzumab) followed by triple-drug maintenance immunosuppression, most commonly tacrolimus, mycophenolate mofetil (MMF), and a corticosteroid such as prednisone.[2][6] This therapy is lifelong. Efforts to minimize maintenance immunosuppression, and ultimately to induce immune tolerance so that less or no chronic medication is needed, are major goals of ongoing research, because the medications themselves drive much of the procedure's risk.[6][12]

Rejection

Acute rejection in hand transplantation is predominantly skin-directed: it usually presents with cutaneous changes such as a maculopapular erythematous rash, and less often with changes in the palm or nail beds.[2][13] Acute rejection is extremely common, occurring in roughly 85% of hand transplant recipients within the first year, though most episodes are reversible with treatment.[2][14] Rejection is monitored and confirmed by skin biopsy and graded using the Banff 2007 working classification of skin-containing composite tissue allograft pathology, developed at the Ninth Banff Conference on Allograft Pathology in La Coruña, Spain, on June 26, 2007. The Banff scheme grades rejection from 0 (no rejection) through I (mild), II (moderate), III (severe), to IV (very severe), based on features including the density of perivascular and epidermal inflammatory infiltrate, epithelial apoptosis, dyskeratosis, and necrosis.[13][15]

Functional outcomes

Functional recovery develops over time as nerves regenerate. Across reported series, recipients have generally regained protective sensibility, with most also recovering tactile sensibility (reported around 90%) and a majority recovering discriminative (fine, two-point) sensibility (reported around 82%).[2][14] Motor function and grip likewise improve gradually, and standardized disability scores such as the DASH (Disabilities of the Arm, Shoulder and Hand) tend to improve after transplantation.[8][16] A majority of recipients report improved quality of life, with figures around 75% in some reviews, though outcomes vary considerably between individuals and depend on amputation level, time since transplant, and adherence to rehabilitation.[14][16]

Complications and graft loss

The principal risks arise from lifelong immunosuppression rather than from the graft surgery itself. Reported complications include opportunistic infections (notably cytomegalovirus), metabolic disorders such as diabetes mellitus and Cushing syndrome, kidney dysfunction, and an elevated risk of certain malignancies, including post-transplant lymphoproliferative disorder.[2][14] Despite the very high incidence of acute rejection, most episodes are reversible, and chronic rejection has been less commonly reported in hand grafts than in some other transplants.[14] Reported one-year graft survival has been high (on the order of 96% in some series), and immune-mediated rejection is the leading cause of graft loss; roughly 10.8% of hand transplants worldwide have ultimately been removed, often related to rejection or non-adherence.[4][2] (Figures are point-in-time estimates from published series and registries.)

History

The first attempt at human hand transplantation was performed in Ecuador in 1964, but immunosuppressive therapy was then in its infancy: a regimen of prednisone and azathioprine could not prevent irreversible acute rejection, and the graft was lost within about two weeks.[3]

The first long-term successful hand transplant was performed on September 23, 1998, in Lyon, France, by an international team led by Jean-Michel Dubernard, with the recipient being Clint Hallam, who had lost his hand in an earlier accident.[9][11] The first hand transplant in the United States followed on January 25, 1999, in Louisville, Kentucky, with recipient Matthew Scott; the Louisville team established protocols that contributed to durable long-term graft survival.[11][9] The first bilateral (double) hand transplant was performed in Lyon, France, in January 2000.[3]

The Clint Hallam graft removal

The Lyon 1998 case, although a technical and immunological milestone, illustrated the central importance of recipient adherence. Hallam did not consistently follow the prescribed immunosuppression and physiotherapy and reportedly never psychologically accepted the transplanted hand, describing a lack of sensation. Acute rejection followed his lapses in medication, and at his request the graft was surgically removed in 2001.[3][9] The case is frequently cited as a cautionary example underscoring why psychological screening and demonstrated capacity for lifelong adherence are emphasized in recipient selection.[3]

Ethics

The defining ethical feature of hand transplantation is that it is a non-life-saving (life-enhancing) procedure that nonetheless commits the recipient to lifelong immunosuppression and its attendant risks of infection, metabolic disease, organ toxicity, and malignancy.[3] Commentators weigh the genuine gains in function, body image, and quality of life against these chronic risks and the substantial lifetime cost relative to prosthetic alternatives.[3] Because long-term data remain limited compared with solid-organ transplantation, ensuring truly informed consent and rigorous candidate selection are recurring ethical themes.[3] Research aimed at reducing or eliminating chronic immunosuppression through tolerance induction is partly motivated by these concerns.[6][12]

Current status

Hand transplantation remains a specialized procedure performed at a small number of centers. Cumulative worldwide totals are modest: approximately 151 hand transplants had been completed through December 2024, including about 38 in the United States, with other significant national totals reported for India, China, England, and France.[4] In the United States, OPTN oversight since 2014 has standardized data collection and reporting for hand and other VCA procedures.[4][5] The field continues to focus on improving functional outcomes, refining rejection monitoring, and developing strategies, such as immune tolerance induction, to reduce the burden and risk of lifelong immunosuppression.[6][12] (Case counts are point-in-time and should be re-confirmed against current registries.)

See also

• Vascularized composite allotransplantation (VCA)
• Face transplantation
• Transplant immunology
• Organ transplantation

References

• Vascularized Composite Allotransplantation. overview. ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/vascularized-composite-allotransplantation
• Current status of vascularized composite tissue allotransplantation. PMC5012023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012023/
• Shores JT, et al. History and ethics of hand transplants. PMC3499956. https://pmc.ncbi.nlm.nih.gov/articles/PMC3499956/
• VCA Background Information and Context. Advancing Face and Hand Transplantation. NCBI Bookshelf, NBK615569. https://www.ncbi.nlm.nih.gov/books/NBK615569/
• Hein RE, et al. Hand transplantation in the United States: A review of the OPTN/UNOS Database. American Journal of Transplantation, 2020. https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15704
• Immunogenicity and tolerance induction in vascularized composite allotransplantation. PMC11235364. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235364/
• Hand Transplantation: The Benefits, Risks, Outcomes, and Future. PMC6379012. https://pmc.ncbi.nlm.nih.gov/articles/PMC6379012/
• Hand Transplant: Procedure, Side Effects & Rejection. Cleveland Clinic. https://my.clevelandclinic.org/health/procedures/hand-transplant
• Hand transplant patients experience both success, failure. Healio. https://www.healio.com/news/orthopedics/20120325/hand-transplant-patients-experience-both-success-failure
• The Current Status of Vascularized Composite Allotransplantation. Clinics in Plastic Surgery. https://www.plasticsurgery.theclinics.com/article/S0094-1298(25)00065-3/abstract
• The Vault: Louisville makes history with world's first successful hand transplant. WHAS11. https://www.whas11.com/article/news/local/the-vault/successful-hand-transplant-the-vault/417-56873f4b-009c-43cb-aece-600a86dd1842
• The Need for Inducing Tolerance in Vascularized Composite Allotransplantation. PMC3509522. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509522/
• Review of the Early Diagnoses and Assessment of Rejection in Vascularized Composite Allotransplantation. PMC3575677. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575677/
• Hand Transplantation: The Benefits, Risks, Outcomes, and Future. PMC6379012. https://pmc.ncbi.nlm.nih.gov/articles/PMC6379012/
• Cendales LC, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. American Journal of Transplantation / PubMed 18444912. https://pubmed.ncbi.nlm.nih.gov/18444912/
• Dandoulakis E, et al. Functional outcomes and innovations in hand transplantation: a systematic overview of the past decade. IJSRA, 2025. https://ijsra.net/sites/default/files/fulltext_pdf/IJSRA-2025-2232.pdf